Copur spoke with CancerNetwork® about the potential for a new era of cancer treatment and immunotherapy with the recent approval of mRNA vaccines to treat COVID-19.
CancerNetwork® sat down with Mehmet Sitki Copur, MD, Medical Director of Oncology, Medical Oncology/Hematology Mary Lanning Healthcare Morrison Cancer Center and Professor, University of Nebraska Medical Center, to discuss his article in the journal ONCOLOGY®, titled “Messenger RNA Vaccines-Beckoning of a New Era in Cancer Immunotherapy.”
Copur discussed how the approval of recent messenger RNA (mRNA) vaccines by the FDA to combat COVID-19 opens a door for the potential future of cancer immunotherapy and mRNA vaccines.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.
Oncology Peer Review On-The-Go: COVID-19, Cancer, and the Potential of mRNA Vaccines
March 30th 2021Mehmet Sitki Copur, MD, discussed his article in the Journal ONCOLOGY® focusing on COVID-19, messenger RNA vaccines, and the excitement surrounding its integration into the future of cancer treatment.
This study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.